Austria

A. Menarini Diagnostics and Nucleix announce a strategic partnership for a non-invasive bladder cancer test in Europe

Florence, Italy, 9 September 2024 - A. Menarini Diagnostics, a company bringing advanced solutions to the in vitro diagnostic market, and Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, announced at the 36th European Congress of Pathology in Florence, that they have entered into a long-term commercial agreement for the exclusive distribution of the Bladder EpiCheck® test in Europe. 

A. Menarini Diagnostics and Sinocare Announce Exclusive Distribution Agreement for New Continuous Glucose Monitoring System

Florence, Italy - 3rd December 2024.  A. Menarini Diagnostics announces an exclusive Distribution Agreement with Sinocare to register, promote, distribute, and market a new Sinocare 3rd Generation Continuous Glucose Monitoring (CGM) System within reimbursed markets. This landmark agreement grants A. Menarini Diagnostics exclusive rights to introduce this health technology to more than 20 jurisdictions in Europe.

123456789

Our values

4 values, which have given life to Menarini and shaped its history

READ MORE »